Entering text into the input field will update the search result below

AstraZeneca's Faslodex successful in late-stage breast cancer study as first-line treatment

May 27, 2016 10:08 AM ETAstraZeneca PLC (AZN) StockBy: Douglas W. House, SA News Editor
  • Results from a Phase 3 clinical trial, FALCON, showed AstraZeneca's (NASDAQ:AZN -0.4%) FASLODEX (fulvestrant) was superior to Arimidex (anastrozole) in extending progression-free survival (PFS) in postmenopausal women with hormone receptor-positive (HR+) breast cancer who had not had prior hormonal treatment. Full results will be presented at an upcoming medical conference (probably ASCO).
  • FASLODEX is currently approved for the treatment of HR+ HER2- breast cancer, in combination with palbociclib in patients previously treated with endocrine therapy and in HR+ breast cancer in patients previously treated with antiestrogen therapy.

Recommended For You

More Trending News

About AZN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
AZN--
AstraZeneca PLC